In a similar approach, Azad et al. evaluated 89Zr-labeled CXCR4 monoclonal antibody (89Zr-CXCR4-mAb) imaging in NSCLC models and revealed enhanced PET uptake in tumors with high CXCR4 expression, with therapeutic responses correlating with CXCR4 levels, supporting its role in precision medicine approaches for lung cancer (Azad et al., 2016). This evidence concerns the gene CXCR4 and lung cancer.